FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891831682> ?p ?o ?g. }

• W2891831682 endingPage "949" @default.
• W2891831682 startingPage "947" @default.
• W2891831682 abstract "Colorectal cancer (CRC) is a significant public health problem and a major focus of research and clinical care for gastroenterologists; thus, changes in CRC practice guidelines confer a large impact on patients, clinicians, health care systems, and insurers. Despite substantial decreases in the incidence of CRC over the last 30 years, cancers of the colon and rectum are still the second leading cause of cancer death in many countries. In the United States, for example, the lifetime risk of CRC is 4.7%, it accounts for >8% of all cancer mortality, and in 2018 there will be an estimated 140,250 incident CRC cases and 50,630 CRC deaths.1Surveillance, Epidemiology, and End Results. Cancer stat facts: colorectal cancer. 2018. Available from: https://seer.cancer.gov/statfacts/html/colorect.html. Accessed July 11, 2018.Google Scholar, 2Peery A.F. Crockett S.D. Barritt A.S. et al.Burden of gastrointestinal, liver, and pancreatic diseases in the United States.Gastroenterology. 2015; 149: 1731-1741 e3Abstract Full Text Full Text PDF PubMed Scopus (598) Google Scholar Endoscopic and fecal-based screening tests markedly reduce the risk of cancer and cancer death.3Siegel R.L. Miller K.D. Fedewa S.A. et al.Colorectal cancer statistics, 2017.CA Cancer J Clin. 2017; 67: 177-193Crossref PubMed Scopus (2998) Google Scholar However, only 62.6% of adults over the age of 50 received either a fecal test in the past year, sigmoidoscopy in the past 5 years, or a colonoscopy in the past 10 years.4American Cancer SocietyCancer facts & figures 2017. American Cancer Society, Atlanta2017Google Scholar In addition, demonstrated disparities in colorectal mortality by race (eg, African Americans) and sex raise questions regarding whom to screen, when to screen, and how to screen most effectively.3Siegel R.L. Miller K.D. Fedewa S.A. et al.Colorectal cancer statistics, 2017.CA Cancer J Clin. 2017; 67: 177-193Crossref PubMed Scopus (2998) Google Scholar, 5Jeon J. Du M. Schoen R.E. et al.Determining risk of colorectal cancer and starting age of screening based on lifestyle, environmental, and genetic factors.Gastroenterology. 2018; 154: 2152-2164 e19Abstract Full Text Full Text PDF PubMed Scopus (180) Google Scholar Guidelines for CRC screening differ somewhat, although there has been a consensus on initiating regular CRC screenings at age 50, among average risk people (Table 1).6European Colorectal Cancer Screening Guidelines Working Group von Karsa L. Patnick J. Segnan N. et al.European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication.Endoscopy. 2013; 45: 51-59Crossref PubMed Scopus (8) Google Scholar, 7American Cancer Society Guideline for Colorectal Cancer Screening. May 30, 2018. Available from: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html. Accessed July 11, 2018.Google Scholar, 8U.S. Preventative Services Task Force. Screening for colorectal cancer: U.S. Preventative Services Task Force Recommendation Statement 2008. Ann Intern Med 627-637.Google Scholar, 9Qaseem A. Denbarg T.D. Hopkins Jr., R.H. et al.Screening for colorectal cancer: a guidance statement from the American College of Physicians.Ann Intern Med. 2012; 156: 378-386Crossref PubMed Scopus (260) Google Scholar, 10Screening, N.C.C.N.P.M.C.C. Colorectal Cancer Screening. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). 2018.Google Scholar, 11Rex D.K. Boland C.R. Dominitz J.A. et al.Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer.Gastroenterology. 2017; 153: 307-323Abstract Full Text Full Text PDF PubMed Scopus (393) Google Scholar The same guidelines also recommend ages to stop routine screening and ages after which point additional screening should be individualized based on preference, risk factors, and estimated life expectancy.Table 1Screening GuidelinesGroupAge to Begin Routine Screening (y)Age to Consult with Physician on Continued Screening (y)Age to Stop Routine Screening (y)US Multi-Society Task Force on Colorectal Cancer50aAt 45 years for African Americans.7585National Comprehensive Cancer Network507685American College of Physicians50bAt 40 years for high-risk adults.—75European Council50—75American Cancer Society457686US Preventative Services Task Force507686a At 45 years for African Americans.b At 40 years for high-risk adults. Open table in a new tab In May 2018, this consensus changed when the American Cancer Society published revised guidelines and provided a qualified recommendation for starting screening for average risk adults at age 45.12Wolf A.M.D. Fontham E.T.H. Church T.R. et al.Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018; 68: 250-281Crossref PubMed Scopus (903) Google Scholar It was a “qualified” rather than a “strong” recommendation because there is compelling evidence of screening benefits, but fewer data regarding the benefit-to-harm ratio and patient preferences, including by modality.12Wolf A.M.D. Fontham E.T.H. Church T.R. et al.Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018; 68: 250-281Crossref PubMed Scopus (903) Google Scholar, 13Naber S.K. Kuntz K.M. Henrikson N.B. et al.Cost effectiveness of age-specific screening intervals for people with family histories of colorectal cancer.Gastroenterology. 2018; 154: 105-116 e20Abstract Full Text Full Text PDF PubMed Scopus (17) Google Scholar, 14van der Vlugt M. Grobbee E.J. Bossuyt P.M.M. et al.Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.Gastroenterology. 2017; 153: 439-447 e2Abstract Full Text Full Text PDF PubMed Scopus (46) Google Scholar Given this relative lack of empirical evidence on screening effectiveness in patients under the age of 50, experts have relied largely on modeling analyses. The modeling team working with the US Preventative Services Task Force, for example, suggested that, for most model screening strategies, beginning at age 45 may provide a favorable balance between life years gained and the cost/risks of more screening.15Knudsen A.B. Zauber A.G. Rutter C.M. et al.Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force.JAMA. 2016; 315: 2595-2609Crossref PubMed Scopus (321) Google Scholar In the end, they did not change their 2016 recommendations, citing a lack of empirical evidence.12Wolf A.M.D. Fontham E.T.H. Church T.R. et al.Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018; 68: 250-281Crossref PubMed Scopus (903) Google Scholar, 15Knudsen A.B. Zauber A.G. Rutter C.M. et al.Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US Preventive Services Task Force.JAMA. 2016; 315: 2595-2609Crossref PubMed Scopus (321) Google Scholar The American Cancer Society, in addition to such modeling studies, noted that, although CRC has been decreasing steadily over the past 2 decades among persons >50 years of age, there has been about a 51% relative increase (although a low absolute incidence) among those <50 years of age12Wolf A.M.D. Fontham E.T.H. Church T.R. et al.Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018; 68: 250-281Crossref PubMed Scopus (903) Google Scholar; other investigators have questioned whether these changes are partially related to increased detection.16Murphy C.C. Lund J.L. Sandler R.S. Young-onset colorectal cancer: earlier diagnoses or increasing disease burden?.Gastroenterology. 2017; 152: 1809-1812 e3Abstract Full Text Full Text PDF PubMed Scopus (47) Google Scholar Additional studies have shown a similar prevalence of large polyps among adults between 45 and 49 and 50 and 54 years of age,12Wolf A.M.D. Fontham E.T.H. Church T.R. et al.Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society.CA Cancer J Clin. 2018; 68: 250-281Crossref PubMed Scopus (903) Google Scholar, 17Lieberman D.A. Holub J.L. Moravec M.D. et al.Prevalence of colon polyps detected by colonoscopy screening in asymptomatic black and white patients.JAMA. 2008; 300: 1417-1422Crossref PubMed Scopus (169) Google Scholar although the extent to which their earlier removal impacts important endpoints is unknown, as well as whether younger patients were from higher risk populations. The initial responses to the American Cancer Society’s recommendation change have been measured, with calls for more evidence on both potential benefits and harms for strategies using varied ages and modalities. Concerns for lowering the screening age centered on appropriate balancing of both risk/benefit and cost/benefit. For example, Bretthauer et al18Bretthauer M. Kalager M. Weinberg D.S. From colorectal cancer screening guidelines to headlines: Beware!.Ann Intern Med. 2018; 169: 405-406Crossref PubMed Scopus (17) Google Scholar estimated that, assuming screening tests decreased CRC mortality by 50% and that screening cost $250 per person (based on a mix of expensive and inexpensive screening modalities), preventing 900 CRC deaths among persons 45 to 49 years of age would have cost $5.5 billion in 2017. The Centers for Disease Control and Prevention, in an electronic communication from Dr Lisa Richardson, the Director of Cancer Prevention and Control, noted that,The Centers for Disease Control and Prevention (CDC) supports use of the U.S. Preventive Services Task Force recommendation to begin screening for colorectal cancer (CRC) at age 50 years. The majority of new cases of colorectal cancer—about 90%, occur in people who are age 50 years or older. Many adults are not currently benefitting from CRC screening, a potential life-saving intervention. While nearly 80% of adults age 65 to 75 years were up to date with colorectal cancer screening in 2016, less than two-thirds of adults age 50 to 64 were up to date. Thus, it is important for CDC-funded programs to focus their limited resources on reaching this group for screening and early detection. In addition, increasing awareness of the importance of CRC screening remains important. CDC supports educating providers and all adults, regardless of age, about the importance of knowing their family history of colorectal and other cancers, and recognizing the symptoms of CRC to seek timely medical care. Moreover, collaborating with partners to increase CRC screening among uninsured, underinsured, low-income, rural, racial and ethnic minorities, and other populations that have disproportionately high burdens of colorectal cancer and lower rates of screening is essential. A joint electronic communication from the Multi-Society Task Force (MSTF) on Colorectal Cancer, a consortium representing the American Gastroenterological Association, The American College of Gastroenterology, and the American Society of Gastrointestinal Endoscopy, stated that,The MSTF has previously recommended that colorectal cancer screening for average-risk persons (persons who do not have a family history of colorectal cancer in a first-degree relative) begin at age 45 years in African Americans and age 50 in other groups. The MSTF has reviewed the recent recommendation from the American Cancer Society (ACS) to lower the age to begin screening from 50 to 45 years in all Americans. This change was a qualified recommendation based largely on a modeling study utilizing updated data on the incidence of colorectal cancer in younger people. Evidence from screening studies to support lowering the screening age is very limited at this time. Based on the modeling study used to support the ACS recommendation, the MSTF recognizes that lowering the screening age to 45 may improve early detection and prevention of CRC. The MSTF expects the new ACS recommendation to stimulate investigation that will clarify the benefits and risks of earlier screening. As the MSTF has previously noted and discussed, rates of colorectal cancer are increasing in Americans down to age 20 years. Beginning screening at 45 years addresses only part of the increasing risk of colorectal cancer in young persons. For all persons under 50 years, it remains critical to promptly assess symptoms consistent with colorectal cancer. In particular, rectal bleeding and unexplained iron deficiency anemia have substantial predictive value for colorectal cancer and should be thoroughly evaluated. Differences in opinion provide key opportunities for research, which, in turns, develops the evidence needed for informed decision making; as the specialty’s leading international journal in gastroenterology, we look forward to vigorous discussions and new investigations regarding when to start screening, when to stop, and how best to better match risk of disease, potential screening benefits, known harms and patient preferences. Such evidence can inform greater consensus regarding when to start and stop CRC screening in different settings. The authors thank Evan Layefsky for his valuable assistance with this commentary. Screening for Colorectal Cancer at Earlier Ages: Putting the Cart before the HorseGastroenterologyVol. 156Issue 5PreviewCorley and Peek wisely titled “When should guidelines change?” in their comment questioning the benefits and risks of screening for colorectal cancer at earlier ages as the American Cancer Society published a revised guideline that recommended for starting screening for average risk adults at age 45.1 Indeed, the updating of guidelines it is too frequently forgotten, despite obsolescent guidelines deny the use of new treatment strategies and allow unfair commercial competition.2 However, the pro and con debate about this new recommendation overlooked the public health issues. Full-Text PDF" @default.
• W2891831682 created "2018-09-27" @default.
• W2891831682 creator A5037291379 @default.
• W2891831682 creator A5047989998 @default.
• W2891831682 date "2018-10-01" @default.
• W2891831682 modified "2023-10-16" @default.
• W2891831682 title "When Should Guidelines Change? A Clarion Call for Evidence Regarding the Benefits and Risks of Screening for Colorectal Cancer at Earlier Ages" @default.
• W2891831682 cites W1222886474 @default.
• W2891831682 cites W1517389415 @default.
• W2891831682 cites W2053380684 @default.
• W2891831682 cites W2083726396 @default.
• W2891831682 cites W2163547654 @default.
• W2891831682 cites W2443966614 @default.
• W2891831682 cites W2594373254 @default.
• W2891831682 cites W2608700489 @default.
• W2891831682 cites W2610540587 @default.
• W2891831682 cites W2622388981 @default.
• W2891831682 cites W2757826586 @default.
• W2891831682 cites W2788766073 @default.
• W2891831682 cites W2805885226 @default.
• W2891831682 cites W2826514084 @default.
• W2891831682 doi "https://doi.org/10.1053/j.gastro.2018.08.040" @default.
• W2891831682 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6364299" @default.
• W2891831682 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30193780" @default.
• W2891831682 hasPublicationYear "2018" @default.
• W2891831682 type Work @default.
• W2891831682 sameAs 2891831682 @default.
• W2891831682 citedByCount "16" @default.
• W2891831682 countsByYear W28918316822019 @default.
• W2891831682 countsByYear W28918316822020 @default.
• W2891831682 countsByYear W28918316822021 @default.
• W2891831682 countsByYear W28918316822022 @default.
• W2891831682 countsByYear W28918316822023 @default.
• W2891831682 crossrefType "journal-article" @default.
• W2891831682 hasAuthorship W2891831682A5037291379 @default.
• W2891831682 hasAuthorship W2891831682A5047989998 @default.
• W2891831682 hasBestOaLocation W28918316821 @default.
• W2891831682 hasConcept C121608353 @default.
• W2891831682 hasConcept C126322002 @default.
• W2891831682 hasConcept C143998085 @default.
• W2891831682 hasConcept C154945302 @default.
• W2891831682 hasConcept C41008148 @default.
• W2891831682 hasConcept C526805850 @default.
• W2891831682 hasConcept C71924100 @default.
• W2891831682 hasConcept C74909509 @default.
• W2891831682 hasConcept C84857602 @default.
• W2891831682 hasConceptScore W2891831682C121608353 @default.
• W2891831682 hasConceptScore W2891831682C126322002 @default.
• W2891831682 hasConceptScore W2891831682C143998085 @default.
• W2891831682 hasConceptScore W2891831682C154945302 @default.
• W2891831682 hasConceptScore W2891831682C41008148 @default.
• W2891831682 hasConceptScore W2891831682C526805850 @default.
• W2891831682 hasConceptScore W2891831682C71924100 @default.
• W2891831682 hasConceptScore W2891831682C74909509 @default.
• W2891831682 hasConceptScore W2891831682C84857602 @default.
• W2891831682 hasIssue "4" @default.
• W2891831682 hasLocation W28918316821 @default.
• W2891831682 hasLocation W28918316822 @default.
• W2891831682 hasLocation W28918316823 @default.
• W2891831682 hasLocation W28918316824 @default.
• W2891831682 hasOpenAccess W2891831682 @default.
• W2891831682 hasPrimaryLocation W28918316821 @default.
• W2891831682 hasRelatedWork W2000479004 @default.
• W2891831682 hasRelatedWork W2055656665 @default.
• W2891831682 hasRelatedWork W2392730113 @default.
• W2891831682 hasRelatedWork W2409949902 @default.
• W2891831682 hasRelatedWork W2473759769 @default.
• W2891831682 hasRelatedWork W3003904233 @default.
• W2891831682 hasRelatedWork W3004259476 @default.
• W2891831682 hasRelatedWork W3039284339 @default.
• W2891831682 hasRelatedWork W3137876420 @default.
• W2891831682 hasRelatedWork W4213156115 @default.
• W2891831682 hasVolume "155" @default.
• W2891831682 isParatext "false" @default.
• W2891831682 isRetracted "false" @default.
• W2891831682 magId "2891831682" @default.
• W2891831682 workType "article" @default.